The potential impact of Brexit on biopharmaceutical R&D in the UK

In our weekly expert view piece Dr Nick Meyers, programme director at Boyd Consultants examines the implications what the regulatory and legislative landscape in the biopharmaceutical industry could look like post-Brexit.

In this article, I aim to explore, without any bias in favour either of remaining in or leaving the EU, some of the practical consequences for biopharmaceutical companies undertaking research and development with a view to commercialising their products, of a potential exit from the European Union; a so-called ‘Brexit’ following the June 23 referendum i.e., what changes might be required, in terms of the way we work on a daily basis.

It is of course formally possible that a vote to leave could trigger a counter proposal from the EU, involving additional concessions, aimed at persuading Britain to remain a member, which would likely require a second referendum to either reverse or reiterate the outcome of the first, in the light of any new deal for the UK.